Group 1: Company Overview - Tianjin Jiuan Medical Electronics Co., Ltd. (referred to as "Jiuan Medical") held an investor online communication meeting on January 28, 2026, discussing product development, diabetes care "O+O" new model, AIoT diabetes home assistant project, sci-tech investment, and shareholder return planning [1] Group 2: IVD Product Progress - Jiuan Medical's IVD product, the iHealth four-in-one test kit, received FDA 510(k) pre-market notification in December 2025 and is now available for sale at CVS and on Amazon, priced at $29.99 for two tests and $49.99 for four tests [2] - The product expands the range of detectable viruses, meeting diverse respiratory virus screening needs in the U.S. market, enhancing core competitiveness [2] Group 3: Diabetes Care "O+O" New Model - The "O+O" model focuses on comprehensive diabetes management, with partnerships established in 424 hospitals across approximately 50 cities in China, managing over 366,000 patients [3] - The model has improved the glycated hemoglobin target rate from around 30% to 60%, with adverse event rates dropping below 5% and management rates increasing to 70% [3] - In the U.S., collaborations with about 74 clinics and 394 doctors are managing approximately 21,000 patients [3] Group 4: AIoT Diabetes Home Assistant - The AIoT diabetes home assistant project aims to develop an intelligent, personalized chronic disease management tool using advanced AI technology, with a complete AI module expected to launch in Q2 2026 [4] - The system is designed to enhance the efficiency of caregivers rather than replace them, utilizing a specialized AI model trained on health data from 366,000 diabetes patients [4] Group 5: Sci-Tech Investment - Since 2022, Jiuan Medical has committed over 4.3 billion yuan to various investment fields, including hard technology, healthcare, AI, and new materials, through partnerships with 27 venture capital funds [5][6] - The focus is on next-generation AI technologies and their applications, aiming for comprehensive coverage of the AI industry chain [6] Group 6: Shareholder Return Planning - Jiuan Medical has canceled 29,954,222 shares of treasury stock and plans to distribute cash dividends amounting to no less than 30% of cumulative net profits over the next three years [7] - The company aims to maintain market value and enhance stock price reflection of intrinsic value through strategic stock repurchases and improved business performance [7]

Core Insights - The company aims to extend its services beyond just providing blood glucose meters to diabetes patients, focusing on comprehensive diabetes management and innovative product development [1][2] - The continuous glucose monitoring (CGM) system is identified as a core product for the company's next strategic development phase, with plans for smart, convenient, and comfortable product iterations [2][3] - The company has maintained an annual R&D investment exceeding 8% of revenue, with a global R&D center set to enhance capabilities in wearable and high-end implantable medical devices [3] Company Overview - Sanofi Biotech is recognized as the "first stock" in China's blood glucose industry and ranks as the fourth largest blood glucose meter company globally, serving over 25 million users across 187 countries [1] - More than 50% of the self-monitoring diabetes population in China uses the company's products, indicating a strong market presence [1] Product Development - The company has successfully launched its second-generation CGM product in China, which has received EU CE-MDR certification, allowing for sales in EU member states [2] - The introduction of artificial intelligence technology for chronic disease management is underway, with the development of SinoGPT facilitating a closed-loop system between diagnosis, hardware, and user data [2][3] Future Directions - The company plans to invest in research and development for technologies such as artificial pancreas and insulin pumps, aiming to provide comprehensive solutions for chronic disease management [3] - The focus will remain on innovation, transitioning from CGM to CXM, and from dynamic blood glucose monitoring to multi-parameter dynamic monitoring [3]